Views & Analysis
Vas Naramsimhan

Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T...

Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D